BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
Real-time Estimate Cboe BZX  -  05/27 12:24:02 pm EDT
0.6450 USD   +2.38%
04/21Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
AQ
04/21Brooklyn ImmunoTherapeutics, Inc. Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
CI
04/19BROOKLYN IMMUNOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Brooklyn ImmunoTherapeutics, Inc.
Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Number of employees : 10 people.
Managers
Name Title Age Since
Howard J. Federoff, Dr. President, Chief Executive Officer & Director 68 2021
Sandra Gurrola Chief Financial Officer 54 2021
Kevin A. D'Amour, Dr. Chief Scientific Officer 48 2021
Roger Sidhu, Dr. Chief Medical Officer 45 2021
Jay Sial Chief Administrative Officer 57 -
Ronald Guido Chief Development Officer 64 2021
Members of the board
Name Title Age Since
Charles Reed Cherington Director 58 2021
Dennis H. Langer, Dr. Independent Director 68 2021
Heather B. Redman Independent Director 56 2022
Erin Suzanne Enright Independent Director 60 2022
Erich Mohr, Dr. Independent Director 67 2021
Howard J. Federoff, Dr. President, Chief Executive Officer & Director 68 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 57,451,937 33,459,286 58.2% 0 0.0% 58.1%
Stock B 0 156,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Charles Reed Cherington 5,894,101 10.3%
Armistice Capital LLC 5,500,000 9.57%
George P. Denny 4,813,802 8.38%
John D. Halpern 4,747,245 8.26%
Novellus LLC 4,216,092 7.34%
Nicholas Jason Singer 2,095,000 3.65%
Cypress Point Wealth Management LLC 1,887,509 3.29%
William A Custard 1,839,521 3.20%
Yiannis A. Monovoukas 1,681,359 2.93%
Naviter Wealth LLC 1,571,107 2.73%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Brooklyn ImmunoTherapeutics, Inc.